Organon & Co. (NYSE:OGN) Given New $16.00 Price Target at Morgan Stanley

Organon & Co. (NYSE:OGN) had its target price reduced by Morgan Stanley from $17.00 to $16.00 in a research report released on Friday,Benzinga reports. They currently have an equal weight rating on the stock.

Separately, TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Organon & Co. currently has an average rating of “Hold” and a consensus target price of $20.80.

Organon & Co. Stock Performance

OGN stock opened at $15.30 on Friday. The company has a market capitalization of $3.94 billion, a P/E ratio of 3.03, a PEG ratio of 0.83 and a beta of 0.76. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The business has a 50-day moving average price of $15.35 and a 200 day moving average price of $17.48. Organon & Co. has a 1-year low of $13.87 and a 1-year high of $23.10.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. As a group, equities research analysts forecast that Organon & Co. will post 3.82 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 13th. Stockholders of record on Monday, February 24th will be paid a dividend of $0.28 per share. The ex-dividend date of this dividend is Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.32%. Organon & Co.’s payout ratio is 22.22%.

Institutional Investors Weigh In On Organon & Co.

A number of large investors have recently modified their holdings of the business. Talon Private Wealth LLC purchased a new stake in shares of Organon & Co. during the fourth quarter worth about $575,000. Schonfeld Strategic Advisors LLC grew its stake in shares of Organon & Co. by 195.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 63,669 shares of the company’s stock worth $950,000 after acquiring an additional 42,103 shares during the last quarter. Northern Trust Corp grew its stake in shares of Organon & Co. by 17.9% during the fourth quarter. Northern Trust Corp now owns 1,914,115 shares of the company’s stock worth $28,559,000 after acquiring an additional 290,134 shares during the last quarter. Aquatic Capital Management LLC purchased a new stake in shares of Organon & Co. during the fourth quarter worth about $327,000. Finally, Oxford Asset Management LLP purchased a new stake in shares of Organon & Co. during the fourth quarter worth about $419,000. Hedge funds and other institutional investors own 77.43% of the company’s stock.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.